Validity and reliability of a Spanish version of the MyMMAT (Malaysia Medication Adherence Assessment Tool) in type 2 diabetes mellitus patients in Veraguas (Panama)
DOI:
https://doi.org/10.60103/phc.v27.e905Keywords:
Assessment of Medication Adherence; Diabetes Mellitus Type 2; Patient Compliance; Surveys and Questionnaires; Reproducibility of ResultsAbstract
Introduction: One of the factors that most affects the control of type 2 diabetes mellitus (DM2) is medication adherence (Adh-DM2). Measuring Adh-DM2 with valid and reliable tools is essential. The objective was to study the validity and reliability of a Spanish version of the MyMMAT in a sample of patients in Veraguas, Panama.
Method: A cross-sectional study was carried out. Patients with DM2 were interviewed by trained pharmacists and asked to answer the questions included in the MyMMAT questionnaire. HbA1C% and other clinical variables were also collected. Internal consistency (reliability) was assessed using Cronbach's alpha and item-total correlation. Construct validity was studied using principal components factor analysis (APCP), and criterion validity was assessed using a ROC curve.
Results: A total of 175 patients were recruited of whom 115 (68 %) were female and the mean age was 60.0 ± 12.0 years. Of the patients, 67.4% (118) had uncontrolled DM2, with a mean HbA1C% of 8.6 ± 2.3. Ninety per cent of patients had a MyMMAT total score under 32 points. The AFCP extracted two factors that explained 59.3 % of the total variance (VTE). Internal consistency was α=0.91 and item-total correlations were all greater than 0.3.
Conclusions: The Veraguas population had poor adherence to prescribed DM2 treatment. The MyMMAT questionnaire provided adequate validity and reliability data in this study sample.
Downloads
References
International Diabetes Federation (IDF). Diabetes Atlas. 10th edition. [monografía en internet]. International Diabetes Federation; 2021[citado 24 de junio de 2025] disponible en: https://fmdiabetes.org/wp-content/uploads/2022/01/IDF_Atlas_10th_Edition_2021-comprimido.pdf
Quintana HK, Moreno Velásquez I, Montenegro Mendoza R, Niño Hall C, Motta J, Roa R. Diabetes mellitus, its prevalence, awareness, and control in Panama: Data from ENSPA 2019, a national cross-sectional study. Medicine (Baltimore). 2023;102(32):e34600. doi:10.1097/MD.0000000000034600
Pérez A, Redondo-Antón J, Romera I, Luís Lizán L, Rubio-de Santos M, Díaz-Cerezo S, et al. Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review. Diabetes Ther. 2024;15(2):325-341. doi:10.1007/s13300-023-01503-4
Díaz MS. Priorizar el control glucémico temprano para reducir las complicaciones micro y macrovasculares en personas con diabetes tipo 2 [internet]. redgedaps.blogspot. 2022. [citado 24 de junio 2025] Disponible en: https://redgedaps.blogspot.com/2022/06/priorizar-el-control-glucemico-temprano.html
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil WN. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470
Piragine E, Petri D, Martelli A, Calderone V, Lucenteforte E. Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis. J Clin Med. 2023;12(5):1981. doi:10.3390/jcm12051981
Iglay K, Cartier SE, Rosen VM, Zarotsky V, Rajpathak SN, Radican L, et al. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin. 2015;31(7):1283-1296. doi:10.1185/03007995.2015.1053048
Moreno Juste A, Gimeno Miguel A, Poblador Plou B, González Rubio F, Aza Pascual-Salcedo MM, Menditto E, et al. Adherence to treatment of hypertension, hypercholesterolaemia and diabetes in an elderly population of a Spanish cohort. Med Clin (Barc). 2019;153(1):1-5. doi:10.1016/j.medcli.2018.10.023
Rodríguez Battikh H, Esquivel Prados E, Conte Valdes E, Martínez Martínez F, Garcia Corpas J. Conocimiento que tiene el paciente con Diabetes Mellitus tipo 2 sobre su enfermedad: revisión sistemática. Ars Pharm. 2024;65(3):258-77. doi: doi.org/10.30827/ars.v65i3.30295
Esquivel-Prados E, Pareja-Martínez E, García‑Corpas JP. Cuestionarios de adherencia al tratamiento antidiabético oral en pacientes con Diabetes Mellitus 2: revisión sistemática. Ars Pharm.2023;64(2):173-186. doi: 10.30827/ars.v64i2.27256
Morisky DE, Ang A, Krousel‐Wood M, Ward HJ. Predictive Validity of a Medication Adherence Measure in an Outpatient Setting. The Journal of Clinical Hypertension. 2008;10(5):348-354. doi:10.1111/j.1751-7176.2008.07572.x
Marcus A. Pay up or retract? Survey creator’s demands for money rile some health researchers [Internet]. 2017 [citado 25 de junio de 2025]. Disponible en: https://www.science.org/content/article/pay-or-retract-survey-creators-demands-money-rile-some-health-researchers
Martínez-Pérez P, Orozco-Beltrán D, Pomares-Gomez F, Hernández-Rizo JL, Borras-Gallen A, Gil-Guillen VF, et al. Validation and psychometric properties of the 8-item Morisky Medication Adherence Scale (MMAS-8) in type 2 diabetes patients in Spain. Aten Primaria. 2021;53(2):101942. doi:10.1016/j.aprim.2020.09.007
Pareja-Martínez E, Esquivel-Prados E, Franco L, García-Corpas JP. Adherence to antihypertensive therapy in community pharmcy: evaluating the psycometric properties of the Morisky Medication Adherence Scale (MMAS-8) translated into spanish. Pilot Study. Latin American Journal of Pharmacy. 2015;34:86-93.
Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118-123. doi:10.1111/j.1524-4733.2008.00400.x
García-Corpas JP, Esquivel-Prados E. Validez y fiabilidad del cuestionario ARMS-e en pacientes con Diabetes mellitus tipo 2. Ars Pharmaceutica (Internet). 2024;65(2):139-145. doi:10.30827/ars.v65i2.30206
Hatah E, Rahim N, Makmor-Bakry M, et al. Development and validation of Malaysia Medication Adherence Assessment Tool (MyMAAT) for diabetic patients. PLoS One. 2020;15(11):e0241909. doi:10.1371/journal.pone.0241909
A1CNow+ system – PTS diagnostics [Internet]. Ptsdiagnostics.com. [citado el 26 de junio de 2025]. Disponible en: https://www.ptsdiagnostics.com/a1cnow-plus-system/
American Diabetes Association. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes- Diabetes Care 2024 [internet]. 2024 [citado 26 de junio de 2025]. Disponible en: https://diabetesjournals.org/care/article/47/Supplement_1/S111/153951/6-Glycemic-Goals-and-Hypoglycemia-Standards-of.html
Sullivan GM, Artino AR. Analyzing and Interpreting Data From Likert-Type Scales. Journal of Graduate Medical Education. 2013;5(4):541-542. doi:10.4300/JGME-5-4-18
Strainer DL, Norman GR, Cairney J. Health Measurement Scales. A Practical Guide to Their Development and Use. 5th ed. Oxford University Press; 2015.
DeVellis, RF. Scale Development: Theory and Applications (Applied Social Research Methods). 3rd Edition. SAGE Publications, Inc; 2011.
Martínez González M, Sánchez-Villegas A, Faulín Fajardo J. Bioestadística amigable. 2a ed. Diaz de Santos; 2006.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jose P. García-Corpas, Hermes Rodríguez Battikh, Eric Conte Valdes, Sara Itzela Gómez Castillo, Fernando Martínez-Martínez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La revista Pharmaceutical Care España se publica bajo una licencia «Creative Commons, Reconocimiento, No Comercial y Compartir Igual 4.0 Internacional» (CC BY-NC-SA 4.0)», que permite a otros compartir el trabajo con un reconocimiento de la autoría del trabajo y la publicación inicial en esta revista (con excepción de los usos comerciales).
Los autores que publican en esta revista están de acuerdo con los siguientes términos:a) Los autores conservan los derechos de autor (derechos morales) y garantizan a la revista el derecho de ser el primer soporte documental publicado del trabajo.
b) Se permite y anima a los autores a difundir la versión del trabajo revisado por pares y aceptada para su publicación (por ejemplo, en repositorios institucionales o temáticos), recomendando hacerlo con la versión final del editor “pdf”, “html” o “xml”).
